Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson JNJ and MerckMRK are leading U.S. healthcare giants, making them natural peers for a head-to-head ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Investing.com - Merck&Co (NYSE: MRK) reported third quarter EPS of $2.58, $0.23 better than the analyst estimate of $2.35. Revenue for the quarter came in at $17.28B versus the consensus estimate of ...

Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Merck (MRK) stock fell over 2% in premarket trading as the company's ... The media company was helped by an internet ...